RTW INVESTMENTS LP
Q4 2025 Form 13-F
NEW YORK, NEW YORK
CIK 0001493215
· CRD 153232
· SEC-registered investment adviser
$10.0B Reported Value Total
RTW INVESTMENTS LP reports 10 total accounts under management (AUM). There are 10 discretionary accounts valued at $14,137,925,887, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
9 funds
· $13.7B gross asset value
Hedge Fund: $13.4B · Private Equity Fund: $284.4M
Source: Form ADV filed 2026-03-30
Reported value
$10.0B
Quarter over quarter
+21.6%
Holdings
91
Top-10 concentration
50.5%
Filing Structure
Reports holdings for
- RTW MASTER FUND LTD · File #028-16671 · Q4 2014 – Q2 2023 · declared by one filing
- RTW Innovation Master Fund Ltd · File #028-19525 · Q1 2019 – Q2 2023 · declared by one filing
- RTW Venture Fund Ltd · File #028-19571 · Q2 2019 – Q2 2023 · declared by one filing
- RTW Special Purpose Fund II, LLC (not a 13F filer in our records) · File #028-19631 · Q3 2019 – Q4 2020
Key People
Form ADV owners & control persons
Roderick Tze Ian Wong
MANAGING PARTNER, CHIEF INVESTMENT OFFICER
Naveen Yalamanchi
PARTNER, PORTFOLIO MANAGER
Robert John Aurigema
PARTNER, CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2025 13F record
Q4 2025 13F filing summary
| Period of report | December 31, 2025 |
|---|---|
| Filed | February 17, 2026 |
| Form | 13F-HR |
| Reported value | $10.0B |
| Positions | 91 |
| Change in reported value | +23.0% |
| New positions | 29 |
| Exited positions | 12 |
| Position turnover | 39.8% |
| Top-10 concentration | 50.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
84 | $11.7B |
|
Q1 2026 13F
Filed May 15, 2026
|
88 | $10.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
91 | $10.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
74 | $8.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
73 | $7.0B |
|
Q1 2025 13F
Filed May 15, 2025
|
68 | $6.5B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
72 | $6.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
68 | $6.9B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
68 | $6.5B |
|
Q1 2024 13F
Filed May 15, 2024
|
69 | $6.8B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
64 | $6.4B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
67 | $4.7B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
62 | $5.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
60 | $4.8B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
77 | $4.9B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
85 | $4.3B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
107 | $3.9B |
|
Q1 2022 13F
Filed May 16, 2022
|
106 | $4.8B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
124 | $6.8B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
120 | $6.6B |
27 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | MDGL MADRIGAL PHARMACEUTICALS INC | $1.2B | 11.63% |
| 2 | INSM INSMED INC | $842.9M | 8.44% |
| 3 | PTCT PTC THERAPEUTICS INC | $588.4M | 5.89% |
| 4 | ARGX ARGENX SE | $566.4M | 5.67% |
| 5 | PTGX PROTAGONIST THERAPEUTICS INC | $441.9M | 4.43% |
| 6 | NTRA NATERA INC | $343.6M | 3.44% |
| 7 | RDNT RADNET INC | $281.0M | 2.81% |
| 8 | TARS TARSUS PHARMACEUTICALS INC | $273.1M | 2.74% |
| 9 | COGT COGENT BIOSCIENCES INC | $269.7M | 2.7% |
| 10 | PEN PENUMBRA INC | $269.4M | 2.7% |
| 11 | IRTC IRHYTHM TECHNOLOGIES INC | $209.7M | 2.1% |
| 12 | APGE APOGEE THERAPEUTICS INC | $204.7M | 2.05% |
| 13 | APLS APELLIS PHARMACEUTICALS INC | $192.6M | 1.93% |
| 14 | ACAD ACADIA PHARMACEUTICALS INC | $190.8M | 1.91% |
| 15 | ESTA ESTABLISHMENT LABS HLDGS INC | $188.7M | 1.89% |
| 16 | STOK STOKE THERAPEUTICS INC | $176.1M | 1.76% |
| 17 | RGEN REPLIGEN CORP | $174.3M | 1.75% |
| 18 | CYTK CYTOKINETICS INC | $172.9M | 1.73% |
| 19 | IMCR IMMUNOCORE HLDGS PLC | $169.0M | 1.69% |
| 20 | AXSM AXSOME THERAPEUTICS INC | $162.2M | 1.62% |
Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.